| Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
|
| 10.01.03 |
Drugs which suppress the rheumatic disease process |
|
|
Golimumab Injection 50mg (Simponi®)
|
 Restricted
|
|
 NICE TA220: Psoriatic arthritis - golimumab
NICE TA225: Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
|
Guselkumab solution for injection 100mg (Tremfya®)
|
Formulary
|
Pre-filled syringes
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
|
Tofacitinib tablets 5mg (Xeljanz®)
|
Restricted
|
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
|
|
|
|
|
| 10.01.03 |
Gold |
|
|
Auranofin (Ridaura®)
|
Formulary
|
Tablets 3mg
|
|
|
Sodium Aurothomalate (Myocrisin®)
|
Formulary
|
Injection 10mg/0.5ml and 50mg/0.5ml
|
|
|
| 10.01.03 |
Penicillamine |
|
|
Penicillamine
|
Formulary
|
Tablets 125mg and 250mg
|
|
|
| 10.01.03 |
Antimalarials |
|
|
Chloroquine Phosphate
|
Formulary
|
Tablets 250mg (base 155mg)
|
|
|
Hydroxychloroquine Sulphate (Plaquenil®)
|
Formulary
|
Tablets 200mg
|
|
|
| 10.01.03 |
Drugs affecting the immune response |
|
|
Abatacept (Orencia®)
|
Restricted
|
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA280: Rheumatoid arthritis - abatacept (2nd line)
|
Adalimumab (Humira®)
|
Restricted
|
Injection 40mg/0.8ml
|
NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
|
Anakinra (Kineret®)
|
Restricted
|
Injection 100mg/0.67ml
|
|
|
Azathioprine
|
Formulary
|
Tablets 25mg and 50mg
|
|
|
Baricitinib tablets (Olumiant®)
|
Restricted
|
-2mg and 4mg tablets
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
|
Brodalumab 210mg/1.5ml solution for injection pre-filled syringes (Kyntheum®)
|
Formulary
|
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
|
Certolizumab Pegol Injection 200mg (Cimzia®)
|
Restricted
|
|
NICE TA186: Rheumatoid arthritis - certolizumab pegol
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
NICE: TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA415:Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
|
Ciclosporin
|
Formulary
|
Capsules 25mg, 50mg and 100mg
Oral solution 100mg/ml
Concentrate for infusion 50mg/ml
|
|
|
Dupilumab (Dupixent®)
|
Formulary
|
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
|
Etanercept (Enbrel®)
|
Formulary
|
Injection 50mg
|
NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
|
Infliximab (Remicade®)
|
Formulary
|
Infusion 100mg
|
NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
NICE TA134: Psoriasis - infliximab
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
|
Leflunomide (Arava®)
|
Formulary
|
Tablets 10mg, 20mg and 100mg
|
|
|
Methotrexate (Metoject®)
|
Formulary
|
Pre-filled pens: 7.5mg, 10mg, 12.5mg, 15mg, 17.5mg, 20mg, 22.5mg and 25mg
|
|
|
Methotrexate tablets 2.5mg
|
Formulary
|
For rheumatology indications and myasthenia gravis. For other indications, see relevant chapters.
|
|
|
Risankizumab (Skyrizi®)
|
Restricted
|
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
|
Rituximab (MabThera®)
|
Restricted
|
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA308: Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)
|
Tocilizumab (RoActemra®)
|
Formulary
|
Infusion 80mg/4ml
|
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
NICE TA247: Rheumatoid arthritis - tocilizumab
NICE TA518: Tocilizumab for treating giant cell arteritis
|
|
|
| 10.01.03 |
Cytokine modulators |
|
|
| 10.01.03 |
Sulfasalazine |
|
|
Sulfasalazine
|
Formulary
|
Tablets 500mg
|
|
|
Sulfasalazine (Salazopyrin EN-Tabs®)
|
Formulary
|
E/C tablets 500mg
|
|
|
| .... |
| Non Formulary Items |
Belimumab Infusion (Benlysta®)
|
Non Formulary
|
120mg and 400mg Vial |
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
|
Methotrexate Pre-Filled Injection (Ebetrex®)
|
Non Formulary
|
|
|
|
Penicillamine (Distamine®)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
"Amber 1" - These are medicines that require significant monitoring and the decision to treat with an AMBER medicine should be made by specialists only |
|
"Amber 2" - These are medicines that require little or no monitoring by the GP, but should only be prescribed in general practice after they have been recommended following specialist referral. |
|
"Red" - Secondary care only |
|
"Double Red" - NOT recommended for prescribing in either primary or secondary care |
|
Traffic light status to be confirmed |
|
May be prescribed in primary and secondary care |
|
|
|
